IQVIA Laboratories wins Vaccine Industry Excellence Award for Best Central/Specialty Laboratory for second consecutive year

RESEARCH TRIANGLE PARK, N.C. – IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, is honored to be recognized as the 2025 Best Central/Specialty Laboratory at the prestigious 2025 Vaccine Industry Excellence (ViE) Awards for the second consecutive year.
Presented annually at the World Vaccine Congress in Washington, D.C., the ViE Awards recognize the most impactful achievements and contributions in the global vaccine industry. With 13 competitive categories, the awards celebrate excellence across the entire vaccine value chain — from research and development to manufacturing and delivery.

The IQVIA Laboratories vaccine team’s dedication to supporting vaccine development through high-quality laboratory services continues to set industry benchmarks.

“Winning this award two years in a row is a testament to IQVIA Laboratories’ unwavering commitment to scientific innovation, operational excellence and global health advancement,” said Tony Brown, VP & GM of Specialty Labs. “This award reflects the passion and expertise of our teams and our continued mission to accelerate vaccine innovation worldwide.”

The World Vaccine Congress is one of the largest and most influential gatherings in the vaccine space, bringing together researchers, industry leaders and policymakers to explore the latest breakthroughs and strategies in vaccine science.

About IQVIA Laboratories
IQVIA Laboratories is a leading global drug discovery and development laboratory services organization offering a comprehensive suite of central laboratory and specialty biomarker services. Our expertise spans central laboratory, genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine, vaccine, ADME, and bioanalytical services. IQVIA Laboratories also brings extensive expertise in antibody drug discovery, biomarker discovery, and decentralized clinical trial laboratory solutions.

With a commitment to scientific excellence and operational efficiency, IQVIA Laboratories supports the entire drug development life cycle across diverse regions and regulatory landscapes, ensuring data integrity and optimizing research to bring life-changing therapies to patients faster. To learn more visit www.labs.iqvia.com.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.